Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Rushing to sales: kiss of death or golden jackpot?

Jean-Louis Roux Dit Buisson discusses the six most common mistakes pharma makes when it comes to creating and implementing a sales strategy. It is early June and the CEO calls me in as she wants help in developing sales for her newly produced...

Articles

How to utilise value demonstration in your pharmaceutical ma...

In this interview, Caroline Gadd explains why it’s never been more important to demonstrate the value of your products and how to incorporate value demonstration into your marketing strategy. With changes to the healthcare landscape coming at this time of cost-containment measures across healthcare in Europe and across the...

Articles

Pharma news highlights: Roche, Sanofi and more

Ed Silverman shares his highlights from the pharma industry over the past four weeks, including the aftermath of Hurricane Sandy, the call for further clinical trial data transparency and the lowering of cancer drug prices. The past few weeks have been filled with interesting and, sometimes, contentious developments in the...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital